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ABSTRACT
Background: Increased consumption of folic acid is prevalent, leading
to concerns about negative consequences. The effects of folic acid on
the liver, the primary organ for folate metabolism, are largely unknown.
Methylenetetrahydrofolate reductase (MTHFR) provides methyl donors
for S-adenosylmethionine (SAM) synthesis and methylation reactions.
Objective: Our goal was to investigate the impact of high folic acid
intake on liver disease and methyl metabolism.
Design: Folic acid–supplemented diet (FASD, 10-fold higher than
recommended) and control diet were fed to male Mthfr
+/+ and
Mthfr
+/2 mice for 6 mo to assess gene-nutrient interactions. Liver
pathology, folate and choline metabolites, and gene expression in
folate and lipid pathways were examined.
Results: Liver and spleen weights were higher and hematologic proﬁles
were altered in FASD-fed mice. Liver histology revealed unusually
large, degenerating cells in FASD Mthfr
+/2 mice, consistent with non-
alcoholic fatty liver disease. High folic acid inhibited MTHFR activity in
vitro, and MTHFR protein was reduced in FASD-fed mice. 5-Methyl-
tetrahydrofolate, SAM, and SAM/S-adenosylhomocysteine ratios were
lower in FASD and Mthfr
+/2 livers. Choline metabolites, including
phosphatidylcholine, were reduced due to genotype and/or diet in an
attempt to restore methylation capacity through choline/betaine-
dependent SAM synthesis. Expression changes in genes of one-carbon
and lipid metabolism were particularly signiﬁcant in FASD Mthfr
+/2
mice. The latter changes, which included higher nuclear sterol regulatory
element-binding protein 1, higher Srepb2 messenger RNA (mRNA), lower
farnesoid X receptor (Nr1h4) mRNA, and lower Cyp7a1 mRNA, would
lead to greater lipogenesis and reduced cholesterol catabolism into bile.
Conclusions: We suggest that high folic acid consumption reduces
MTHFR protein and activity levels, creating a pseudo-MTHFR de-
ﬁciency. This deﬁciency results in hepatocyte degeneration, suggest-
ing a 2-hit mechanism whereby mutant hepatocytes cannot accommodate
the lipid disturbances and altered membrane integrity arising from
changes in phospholipid/lipid metabolism. These preliminary ﬁnd-
ings may have clinical implications for individuals consuming high-
dose folic acid supplements, particularly those who are MTHFR
deﬁcient. Am J Clin Nutr 2015;101:646–58.
Keywords choline metabolism, folic acid, lipid metabolism, liver,
methylenetetrahydrofolate reductase
INTRODUCTION
Folates are required for nucleotide synthesis and S-adenosylmethionine
(SAM)
6–dependent methylation reactions (Supplemental Figure 1).
Folic acid is a synthetic folate added to fortiﬁed foods and nu-
tritional supplements. Fortiﬁcation has reduced the incidence of
neural tube defects (1, 2) and other disorders (3), but there are
concerns that high folic acid intake, due to fortiﬁcation and vitamin
supplementation, may negatively affect health (4, 5). Recent Na-
tional Health and Nutrition Examination Survey data showed that
w25% of children and 5% of adults older than 50 y consume more
than the recommended upper limit for folic acid (6–8). Un-
metabolized folic acid (UFA) appears in plasma after consuming
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supplements contain $400 mg, and supplement users in the Fra-
mingham cohort were 2.3-fold more likely to have high cir-
culating UFA than nonusers (10). Supplements containing
4000–5000 mg/d are recommended to women with high-risk
pregnancies (11, 12). In an elderly population administered 5000
mg/d for 3 wk, UFA was found in 100% of the study group
(compared with 26% at baseline), and concentrations rose from
0.8% to 15% of total folates (13).
The possible negative effects of high folic acid consumption
have prompted investigations into its impact on health. We found
that pregnancy losses and embryonic heart defects were more
common in mice consuming a diet high in folic acid (14). Other
researchers have suggested links between circulating UFA and
lower cognitive test scores (15), as well as impaired immune
function (16) in humans.
The liver is an important organ in folate metabolism; most
folate-dependent enzymes and the majority of folate are found
there (17). Nonetheless, the effect of high folic acid consumption
on the liverhas not been well examined. UFA may affect the liver
through mechanisms such as enzyme inhibition, either directly
(18–23) or through its metabolites (24–26). The impact of UFA
may be modulated by genetic variants in these enzymes.
Methylenetetrahydrofolate reductase (MTHFR) produces
methyltetrahydrofolate for remethylation of homocysteine to
methionine by methionine synthase (Supplemental Figure 1). In
the liver and kidney, an alternate pathway uses betaine to
remethylate homocysteine through betaine-homocysteine meth-
yltransferase (27) linking choline metabolism to folate metab-
olism. We observed increased ﬂux through betaine-homocysteine
methyltransferase when folate metabolism was disturbed in
humans (28, 29) and mice (28, 30) due to MTHFR mutation (28)
or low dietary folate (30). We found that male mice relied more
on the betaine pathway than did female mice, resulting in greater
susceptibility to hepatic steatosis (30).
In this report, we examine the effects of high folic acid
consumption on the liver. To investigate diet and gene variant
interactions,weusedmicewithmildMTHFRdeﬁciency,amodel
for the MTHFR 677 C.T polymorphism, the most studied
variant in folate metabolism with 5–20% homozygosity (31).
METHODS
Mice, diets, and sample collection
All experiments were performed within the guidelines of the
Canadian Council on Animal Care and approved by the Animal
Care Committee of the Research Institute of the McGill Uni-
versity Health Centre. BALB/c Mthfr
+/+ and Mthfr
+/2 males (32)
were placed on control (CD) and 103 folic acid–supplemented
(FASD) amino acid–deﬁned diets (Harlan) at weaning. CD
(TD.01369) contained 2 mg/kg folic acid, the Recommended
Dietary Allowance (RDA) for rodents set by the American In-
stitute of Nutrition (33), whereas FASD (TD.09258) contained
20 mg/kg diet (103 RDA); both diets contained 2.5 g/kg choline
bitrate, 3.3 g/kg L-methionine, and 1% succinylsulfathiazole (to
inhibit folate production by intestinal ﬂora). Litters were ran-
domly assigned to CD or FASD to produce a total of 7–8 mice in
each of the 4 diet/genotype experimental groups (29 total). Mice
were housed under speciﬁc pathogen-free conditions in a con-
trolled environment (12 h/12 h light/dark cycle, 18–248C) with
ad libitum access to food and water.
After 6 mo on diets, mice were sacriﬁced in random order by
CO2 asphyxiation and body weights recorded. Blood was col-
lected by cardiac puncture in potassium-EDTA–coated tubes.
Complete blood counts were performed at the Animal Resource
Center, McGill University. Plasma was obtained by centrifuga-
tion at 3000 3 g for 7 min and stored at 2758C or below.
Tissues were collected, weighed, and rinsed with cold phos-
phate-buffered saline. The entire left lobe of the liver was ﬁxed
in 4% paraformaldehyde for 1 d and stored at 48C in 70% eth-
anol; the remaining tissue was snap frozen on dry ice and stored
at 2758C or below.
Histologic examination
Fixed liver was embedded in parafﬁnand cut in 5-mm sections.
Sections were stained with hematoxylin and eosin or Masson’s
trichrome stain (Polysciences Inc.). Two hematoxylin and eosin–
stained sections per mouse were examined in random order at
1003, 2003, and 4003 magniﬁcation (2 ﬁelds per section) and
scored for the presence of degenerating cells and lipid droplets
by a blinded observer and conﬁrmed by a second observer.
Degenerating cells were enlarged, contained strands of eosino-
philic material, and had clearing of the cytoplasm. Preliminary
inspection showed that the liver sections fell into 2 groups: 1)n o
or small localized foci of degenerating cells or 2) large numbers
of degenerating cells affecting at least half of the section.
Therefore, livers were scored as containing degenerating cells if
more than half of the hepatocytes in the ﬁeld at 2003 were
affected in at least 3 of the 4 ﬁelds examined (i.e., small lo-
calized foci were not considered meaningful). Accumulation of
lipid droplets (microvesicular and macrovesicular) was graded
as described (30).
MTHFR inhibition assays
Brain and liver extracts for enzyme assays were prepared from
w50 mg frozen tissue under native conditions [lysis buffer:
50 mmol/L potassium phosphate, 0.3 mmol/L EDTA, supple-
mented with protease (Roche) and phosphatase inhibitors
(Thermo Scientiﬁc)] by using a bead mill and cleared by cen-
trifugation. Protein concentration was determined by Bradford
assay by using bovine serum albumin as a standard. Activity
assays were performed as in Goyette et al. (34) with the fol-
lowing modiﬁcations: the assay mix was modiﬁed to contain
200 mmol/L substrate and 30 mmol/L ﬂavin adenine dinucleotide.
Then, 1.4 mmol/L folic acid in 3.5 mmol/L NaOH was added to
the assay to ﬁnal concentrations of 0, 250, 500, and 750 mmol/L,
and 3.5 mmol/L NaOH was added to each reaction to equalize
the ﬁnal concentration of NaOH in each reaction. Assays were
performed in triplicate. Results are expressed as percent
MTHFR activity at 0 mmol/L folic acid and reported as the
mean 6 SEM of 2 (brain) or 3 (liver) separate experiments.
Western blotting
Total liver extracts were prepared as for MTHFR assays (see
previous paragraph). Nuclear and cytoplasmic fractions were
isolated by using the NE-PER Nuclear Protein Extraction Kit
(Thermo Scientiﬁc) following the manufacturer’s instructions.
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 Protein concentration was determined by Bradford assay by
using bovine serum albumin as a standard. Western blotting was
performed with conventional methods by using 25 mgt o t a lo r
cytoplasmic protein or 15 mg nuclear protein. Primary antibodies
were sterol regulatory element-binding protein (SREBP-1; Santa
Cruz Biotechnology), cyclic AMP-responsive element-binding
protein (Cell Signaling Technology), b-actin (Sigma-Aldrich),
and MTHFR (35). Secondary antibody was horseradish per-
oxidase–coupled anti–rabbit IgG (GE Healthcare). Bands were
visualized with Amersham ECL Prime Western Blotting De-
tection Reagent (GE Healthcare) and ﬁlm exposure and
quantiﬁed by densitometry by using Quantity One 1-D Anal-
ysis Software version 4.6.9 (Bio-Rad). Results were normal-
ized to the b-actin loading control and reported relative to the
mean value for CD-fed Mthfr
+/+ mice, which was standardized
to a reference value of 1.
Alkaline phosphatase treatment
Alkaline phosphatase treatment of protein extracts was
adapted from Yamada et al. (36). Brieﬂy, total liver extract was
isolated in RIPA lysis buffer (denaturing conditions: 150 mmol/L
NaCl, 50 mmol/L Tris-HCl, 1 mmol/L EDTA, 1% NP-40, 0.5%
sodium deoxycholate, and 0.1% SDS) supplemented with pro-
tease inhibitors. Then, 50 mg protein was treated with 25 units of
calf intestinal alkaline phosphatase (Roche), incubated at 378C
for 1 h, and analyzed for MTHFR by Western blotting.
Folates
Thedistributionoffolatesinfrozenliver[speciﬁcally:folicacid,
dihydrofolate, tetrahydrofolate (THF), methenylTHF, methyl-
eneTHF, methylTHF, and formylTHF] was determined by liquid
chromatography–electrospray ionization tandem mass spectrom-
etry. Samples were prepared as described in Christensen et al.
(37). Analytes were resolved by reversed-phase chromatography
and measured as described previously (37–39). Total folates are
reported as nmol/g liver; the concentration of individual folate
forms was normalized to total folate concentration and reported as
the percentage of total folates to allow comparison of distributions.
Choline metabolites
The concentrations of choline metabolites in frozen liver were
measured by liquid chromatography–mass spectrometry. Cho-
line, betaine, glycerophosphocholine, phosphocholine (PCho),
phosphatidylcholine (PtdCho), sphingomyelin (SM), and lyso-
phosphatidylcholine (LysoPtdCho) were measured by using the
method in Koc et al. (40), with modiﬁcations (29, 41). SAM
and S-adenosylhomocysteine (SAH) were determined by liquid
chromatography–mass spectrometry as described (42), with modi-
ﬁcations based on our instrumentation (43).
Quantitative reverse transcriptase–polymerase chain
reaction
Total RNAwas extracted from w10 mg frozen liver by using
the RNeasy Mini kit with on-column DNase I treatment (Qia-
gen). Complementary DNA synthesis was performed as in
Knock et al. (44). Quantitative reverse transcriptase–polymerase
chain reaction (RT-PCR) was performed by using Platinum
SYBR Green qPCR SuperMix-UDG master mix (Invitrogen) on
a Lightcycler LC480 (Roche Diagnostics). The following reference
genes were evaluated: b-actin (Actb), b-2-microglobulin (B2m),
succinate dehydrogenase (Sdha), and tyrosine 3-monooxygenase/
tryptophan 5-monooxygenase activation protein, zeta polypeptide
(Ywhaz) [all primers as in Christensen et al. (30)] and glyceralde-
hyde-3-phosphate dehydrogenase (Gapdh)[ p r i m e r sa si nL e c l e r c
et al. (45)]. The 3 most stably expressed reference genes were
determined (Gapdh, Actb,a n dB2m) and used to calculate one
normalization factor for target gene expression by geNorm v.3.4
(Ghent University Hospital Center for Medical Genetics) (46).
Primers for the target genes betaine-homocysteine methyltransfer-
ase (Bhmt) and methionine synthase (Mtr) were reported in
Christensen et al. (30). Primers for Bcl2-like 1 (Bcl-XL) and BCL2-
antagonist/killer 1 (Bak) were reported in Garcia-Crespo et al. (47).
All other target gene primers [choline dehydrogenase (Chdh); cy-
tochrome P450, family 7, subfamily a, polypeptide 1 (Cyp7a1);
fatty acid desaturase 2 (Fads2); methionine adenosyltransferase I, a
(Mat1a); nuclear receptor subfamily 1, group H, member 4
(Nr1h4); farnesoid X receptor (FXR); phosphatidylethanolamine
N-methyltransferase (Pemt); patatin-like phospholipase domain
containing 2 (Pnpla2); peroxisome proliferator-activated receptor a
(Ppara); stearoyl–coenzyme A desaturase 1 (Scd1); sterol regula-
tory element-binding transcription factor 1 (Srebp1); and sterol
regulatory element-binding transcription factor 2 (Srebp2)] were
designed by using Primer-BLAST (National Center for Bio-
technology Information) (48). For a complete list of primer se-
quences and reaction conditions, see Supplemental Table 1.
Quantitative CpG methylation analysis
Using a panoply of analysis tools, CpG islands or similar features
could not be identiﬁed in the Cyp7a1 gene or its vicinity (data not
shown). However, 2 CpG sites in the Cyp7a1 gene were identiﬁed
as potentially differentially methylated because of a DNA region
reported to contain methylation ﬂags (49) and were assessed by
bisulﬁte pyrosequencing as previously described (45). Brieﬂy, ex-
tracted DNA was subjected to bisulﬁte treatment by using the
Epitect Bisulﬁte Kit (Qiagen). Primers for pyrosequencing of
Cyp71a were designed with PyroMark Assay Design 2.0 software
(Qiagen) (5#-biotinylated oligonucleotide: 5#-ACCTTCTCCA-
TATCATCAAAAATAAAAAAT-3#, sense PCR primer: 5#-
AAGTTAGGGAAAGGTTGGTTGAGAG-3#, sequencing primer:
5#-GAATTTGTATATGAGGGATTAG-3#). Pyrosequencing was
performed on the PyroMark Q24 Platform (Qiagen). Data were
interpreted with PyroMark Q24 2.0.6 analysis software.
Caspase 3/7 activity
Total liver extracts were prepared as for MTHFR assays (see
above). Caspase activity was measured with the Caspase-Glo 3/7
Assay System (Promega) by using 2 mg total liver extract in
50 mL assay reagent following the manufacturer’s instructions.
Luminescence was measured with a Glo-max Multi Detection
Microplate reader (Promega).
Statistical methods
All results are expressed as mean 6 SE. Because this pre-
liminary study involved the use of a new diet, with unpredictable
effects, we did not perform a sample size calculation. Sample
sizes were determined based on previous experience with these
648 CHRISTENSEN ET AL.
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 methods in our mouse models (30, 37). Unless noted, data were
analyzed by using 2-factor ANOVAwith diet and genotype as the
independent variables, followed by post hoc analysis by Tukey to
correct for multiple comparisons if the interaction term was sig-
niﬁcant or borderline signiﬁcant (P # 0.058 where indicated).
Effect of folic acid on MTHFR activity was assessed by using
1-factor ANOVA for comparison with the 0-mmol/L folic acid
control, with post hoc analysis by Tukey. Incidence of degen-
erating hepatocytes was assessed by exact binary logistic re-
gression for diet and genotype with individual mice as the unit
of analysis by using SAS version 9.4 (SAS Institute). Statistical
outliers were identiﬁed by using Grubb’s test (QuickCalcs;
GraphPad Software) and removed from the analysis. No other
corrections were made for multiple testing. Results of statistical
tests were considered signiﬁcant at P # 0.05 and borderline
signiﬁcant up to P # 0.075 where indicated. Statistical analyses
were carried out by using SPSS version 20.0.0 (SPSS Inc.) un-
less noted.
RESULTS
FASD consumption affects organ weights and hematology
Liver and spleen weights (adjusted for body weight) of mice
fed FASD were signiﬁcantly higher than those of mice fed CD
(Table 1). These particular organs may be sensitive to folate
intake due to their roles in folate metabolism and hematopoiesis.
White blood cell counts (speciﬁcally lymphocytes) were sig-
niﬁcantly higher in Mthfr
+/2 mice compared with Mthfr
+/+, but
this difference was not affected by diet (Table 2). In contrast,
red blood cell (RBC) counts and related hematologic parameters
were signiﬁcantly affected by both diet and Mthfr genotype,
with more marked changes in the FASD-fed Mthfr
+/2 group
(Table 2). The reduction in RBC counts, hematocrit, and he-
moglobin because of FASD and genotype and the larger mean
corpuscular volume because of FASD are reminiscent of the
megaloblastic anemia associated with folate deﬁciency.
Liver histologic examination reveals that the combination
of MTHFR deﬁciency and high folic acid consumption
causes liver injury
Examination of hematoxylin and eosin–stained sections re-
vealed histologic changes associated with nonalcoholic fatty
liver disease (NAFLD). Considerable numbers of unusually
large cells with vacuolation of the cytoplasm, consistent with
hydropic degeneration or hepatocyte ballooning, were observed
(Figure 1). Both diet and genotype signiﬁcantly affected the
incidence of degenerating cells. However, it is clear from in-
spection of the data (Figure 1C) that these results are driven by
TABLE 1
Mice fed the FASD have higher liver and spleen weights
1
Characteristic
CD FASD 2-Factor ANOVA P value
Mthfr
+/+ Mthfr
+/2 Mthfr
+/+ Mthfr
+/2 Genotype Diet Interaction
Body weight, g 29.8 6 1.2
2 28.2 6 1.2 28.6 6 0.9 29.7 6 1.2 0.831 0.897 0.224
Organ weight (as % body weight)
Liver 4.02 6 0.20 4.00 6 0.23 4.37 6 0.16 4.95 6 0.07 0.118 0.001 0.105
Spleen 0.28 6 0.01 0.31 6 0.02 0.34 6 0.03 0.36 6 0.04 0.389 0.046 0.970
Brain 1.54 6 0.07 1.58 6 0.04 1.58 6 0.04 1.47 6 0.02 0.451 0.469 0.128
1n = 6–8 per group. CD, control diet; FASD, folic acid–supplemented diet.
2Mean 6 SE (analyzed by 2-factor ANOVA; all such values).
TABLE 2
Complete blood counts of CD- and FASD-fed Mthfr
+/+ and Mthfr
+/2 mice reveal hematologic changes because of both
diet and MTHFR deﬁciency
1
Characteristic
CD FASD 2-Factor ANOVA P value
Mthfr
+/+ Mthfr
+/2 Mthfr
+/+ Mthfr
+/2 Genotype Diet Interaction
Red blood cells
Count, 310
12/L 12.82 6 0.28
2 11.80 6 0.50 11.55 6 0.84 9.67 6 0.75 0.036 0.015 0.510
Hematocrit, L/L 0.624 6 0.015 0.573 6 0.023 0.571 6 0.040 0.488 6 0.035 0.040 0.036 0.611
Hemoglobin, g/L 196 6 3 189 6 8 191 6 5 163 6 10 0.020 0.038 0.165
MCV, fL 48.6 6 0.3 48.7 6 0.2 49.4 6 0.4 50.6 6 0.5 0.082 0.001 0.167
MCH, pg 15.3 6 0.2 16.0 6 0.1 15.9 6 0.3 17.0 6 0.3 0.003 0.012 0.410
MCHC, g/L 315 6 6 329 6 3 320 6 7 334 6 3 0.010 0.332 0.989
White blood cells
Count, 310
9/L 5.9 6 0.8 7.8 6 0.9 6.3 6 0.9 8.5 6 0.8 0.026 0.501 0.862
Neutrophils, % 32 6 42 8 6 53 2 6 22 6 6 1 0.167 0.696 0.774
Lymphocytes, % 68 6 47 2 6 56 8 6 27 4 6 1 0.183 0.764 0.816
Neutrophils, 310
9/L 1.45 6 0.13 2.01 6 0.21 1.98 6 0.29 2.35 6 0.29 0.081 0.098 0.719
Lymphocytes, 310
9/L 3.95 6 0.47 5.78 6 0.97 4.34 6 0.67 6.15 6 0.58 0.015 0.595 0.992
Platelets, 310
9/L 865 6 70 899 6 51 901 6 41 1032 6 31 0.122 0.114 0.352
1n = 6–8 per group. CD, control diet; FASD, folic acid–supplemented diet; MCH, mean corpuscular hemoglobin;
MCHC, mean corpuscular hemoglobin concentration; MCV, mean corpuscular volume.
2Mean 6 SE (analyzed by 2-factor ANOVA; all such values).
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 the FASD Mthfr
+/2 group, as 6 of 7 of FASD Mthfr
+/2 livers
presented with this phenotype, compared with a maximum of 1 of 7
in the other groups. Hydropic degeneration, caused by accumula-
tion of ﬂuid in the cytoplasm, is associated with disturbed mem-
brane integrity (50). Changes in membrane integrity can result from
disruption of phospholipid metabolism, because phospholipids,
especially phosphatidylcholine (PtdCho), are critical components
of membranes (51).
Lipid droplets were also observed, as previously reported in
Mthfr
+/2 mice and in mice fed control or low-folate diets (30,
52). The incidence and degree of steatosis in CD-fed mice was
consistent with our previous observations of mice fed CD for
12 mo (30). The accumulation of lipids did not appear to be dif-
ferent between the CD
+/+,C D
+/2, and FASD
+/+ groups (data not
shown). Accurate evaluation of lipid droplet accumulation was
extremely difﬁcult for livers with large numbers of degenerated
cells; therefore, the extent of steatosis in FASD
+/2 mice could
not be determined. It is possible that lipid accumulation is
a precursor to degeneration; additional experimentation would
be required to assess. Masson’s trichrome–stained sections were
also examined; no unusual collagen staining was observed (data
not shown), indicating that liver damage in these mice had not
yet progressed to ﬁbrosis.
MTHFR activity is inhibited by folic acid in vitro, and
immunoreactive protein levels are reduced in FASD-fed
mice
Folic acid has previously been reported to inhibit MTHFR
activity in crude brain extract (21). Because our extraction and
assay methods differed from that report, we assessed the in-
hibition of MTHFR by folic acid in crude brain extract (Figure
2A). MTHFR was also inhibited in crude liver extract (Figure 2B).
Half-maximal inhibition of MTHFR was observed at 750 mmol/L
folic acid (,4-fold substrate concentration), suggesting that UFA
could contribute to MTHFR deﬁciency.
Totalimmunoreactive MTHFRproteinwas reduced inMthfr
+/2
livers as expected. However, MTHFR protein was also affected
by FASD (Figure 2C,E). The upper band in Figure 2C was
identiﬁed as the phosphorylated 70-kDa isoform of MTHFR
(36) by treatment with alkaline phosphatase (Figure 2D). The
relative proportion of phosphorylated and nonphosphorylated
MTHFR was sensitive to both diet and MTHFR deﬁciency
(Figure 2C,F). The percentage of phosphorylated MTHFR,
which is less active than the nonphosphorylated form (36), rose
signiﬁcantly in FASD
+/+ compared with CD
+/+. Overall, the
immunoblotting data suggest that MTHFR activity was reduced
in the liver of FASD-fed mice through reduced protein levels
and greater phosphorylation.
Methylation capacity is reduced in the livers of FASD-fed
mice
Key folate derivatives were evaluated in the liver (Figure 3
and Supplemental Table 2). There was no signiﬁcant change in
the concentration of total folate due to diet or genotype (Figure
3A), as previously observed in mice fed folate-supplemented
diets (53). Therefore, to compare folate distributions, individual
concentrations were normalized to the total and expressed as
percent total folates. Folic acid in the liver was w60% greater in
mice fed FASD (Figure 3B). MethylTHF was lower in all groups
compared with CD
+/+ (Figure 3C), consistent with reduced ex-
pression and activity of MTHFR (Figure 2). There were
no signiﬁcant changes due to diet or genotype in the proportion
of other folates (dihydrofolate, THF, methenylTHF, methyl-
eneTHF, and formylTHF) (Supplemental Table 2). These ﬁnd-
ings suggest that the substrate of MTHFR, methyleneTHF, is
being redistributed among the other nonmethyl forms. High folic
acid intake appears to be altering methylation potential, without
dramatically changing the availability of folate substrates for
nucleotide synthesis and other functions. However, some vari-
ability between mice in the levels of non-methylTHF may have
contributed to this lack of signiﬁcance.
The concentration of SAM is affected in the same manner as
methylTHF (Figure 3D), demonstrating that reduced MTHFR
activity affects the supply of methionine for SAM synthesis. The
concentration of SAH did not change due to either diet or ge-
notype alone, although the interaction between those variables
was signiﬁcant (Figure 3E), suggesting that an effect of FASD on
SAH levels is genotype dependent. It was not possible to resolve
this interaction due to lack of statistical power. However, the
more critical indicator of methylation capacity, the SAM/SAH
ratio (Figure 3F), was lower in all groups relative to CD
+/+. The
graphs in Figures 2E, 3C, 3D, and 3F have very similar patterns,
FIGURE 1 High folic acid consumption in Mthfr
+/2 mice may cause degeneration of hepatocytes. Hematoxylin and eosin–stained liver sections from (A)
CD
+/2 and (B) FASD
+/2 mice (4003 magniﬁcation). Most cells in FASD Mthfr
+/2 liver appear unusually large with clear patches in the cytoplasm consistent
with hepatocyte degeneration. In contrast, most livers of the other 3 groups appeared normal or had only isolated abnormal cells. Examples of these unusual
cells are indicated by arrows. (C) Incidence of widespread degenerating hepatocytes in diet/genotype groups (n = 7–8 per group). Both diet (P = 0.016;
estimated OR: 25.0) and genotype (P = 0.009; estimated OR: 28.9) had signiﬁcant effects on the incidence of widespread degeneration (exact binary logistic
regression). CD, control diet; FASD, folic acid–supplemented diet.
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 consistent with reduced MTHFR protein leading to impaired
methylTHF production with consequent reduction of SAM and
SAM/SAH ratios.
Expression of methylation cycle genes is altered in FASD-
fed mice
The expression of some critical genes in methylation—Mtr,Bhmt,
Chdh, Mat1a,a n dPemt (pathways in Supplemental Figure 1)—was
evaluated by quantitative RT-PCR. These genes code for enzymes
required for the supply and use of SAM in liver. Mtr and Bhmt
catalyze the methylTHF-dependent and betaine-dependent re-
methylation of homocysteine to methionine, respectively. CHDH
catalyzes the ﬁrst, committed step in the metabolism of choline to
betaine. MAT1A synthesizes SAM from methionine and ATP,
whereas PEMT produces PtdCho from phosphatidylethanolamine
(PE), consuming 3 molecules of SAM. The expression of Mtr,
Chdh,a n dPemt w a ss i g n i ﬁ c a n t l yr e d u c e di nF A S D - f e dm i c e ;
Mat1a expression tended to be lower (P = 0.076), and Bhmt
expression did not change (Figure 4). Reduced Mtr was pre-
viously reported in the livers of mice fed a folate-deﬁcient diet
(30) and suggests a shift toward folate-independent homocysteine
remethylation due to reduced methylTHF substrate. A similar
feedback mechanism could be lowering the expression of Pemt as
a result of reduced SAM.
Choline and phospholipid metabolite concentrations are
changed in Mthfr-deﬁcient mice, particularly when fed
FASD
Hepaticconcentrationsofcholineandrelatedmetaboliteswere
measured (Figure 5 and Supplemental Table 2). The concen-
tration of choline did not change signiﬁcantly, consistent with
previous observations that choline stores in liver resist depletion
(30, 54, 55). Betaine concentrations, on the other hand, dropped
signiﬁcantly as a result of FASD in Mthfr
+/2 mice, suggesting
greater use of betaine for homocysteine remethylation when
methylTHF abundance is reduced. Concentrations of PCho,
a choline storage form and intermediate in the cytidine-
diphosphocholine (CDP) choline pathway for PtdCho synthesis,
were also signiﬁcantly lower due to the Mthfr
+/2 genotype, as
were the concentrations of PtdCho and its catabolite SM, with
borderline signiﬁcance for another catabolite, LysoPtdCho (P =
0.057). These observations suggest that there is greater reliance
FIGURE 2 MTHFR activity is inhibited by folic acid in vitro, and immunoreactive protein levels are reduced in FASD-fed mice. MTHFR enzyme activity
assayed in crude brain (A) and liver (B) extracts is reduced with increasing amounts of folic acid. Assays were performed in triplicate and reported as the
means 6 SEMs of 2 (brain) or 3 (liver) separate experiments. *Signiﬁcantly different from 0 mmol/L folic acid, 1-factor ANOVA, Tukey post hoc, P , 0.05.
(C) Representative Western blot of liver extracts from CD-fed and FASD-fed Mthfr
+/+ and Mthfr
+/2 mice. MTHFR appears as a doublet of the phosphorylated
and nonphosphorylated 70-kDa isoform. (D) Alkaline phosphatase treatment of liver extracts conﬁrms that the upper band is the phosphorylated 70-kDa
isoform of MTHFR (experiment performed in duplicate). (E) Quantiﬁcation of MTHFR immunoreactive protein shows that MTHFR expression is reduced
w40% in Mthfr
+/+ mice fed FASD compared with CD; MTHFR expression is reduced w60% in Mthfr
+/2 mice compared with Mthfr
+/+ mice (n = 5 per group,
mean 6 SEM, 2-factor ANOVA). (F) The proportion of phosphorylated MTHFR is signiﬁcantly lower because of the Mthfr
+/2 genotype but higher because of
the FASD (n = 5 per group, mean 6 SEM, 2-factor ANOVA). White bars: Mthfr
+/+; gray bars: Mthfr
+/2. CD, control diet; D, diet; FASD, folic acid–
supplemented diet; G, genotype; MTHFR, methylenetetrahydrofolate reductase.
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 on choline metabolism to support the methylation cycle when
MTHFR is deﬁcient.
Expression of genes in lipid and cholesterol metabolism is
altered by high folic acid consumption, particularly in
Mthfr-deﬁcient mice
The expression of several important genes/proteins in cho-
lesterol and lipid metabolism was evaluated (Figure 6). Many of
these genes have been shown to be involved in NAFLD (56–59).
Sterol regulatory element-binding protein (SREBP) 1 and 2 are
important transcriptional regulators of genes in lipogenesis and
cholesterol biosynthesis, respectively, although there is overlap
between the pathways. FXR (Nr1h4) is a master regulator that
inﬂuences the expression of genes involved in bile acid (cho-
lesterol), lipid, and glucose metabolism (60). SREBP-1 activity
is downregulated by FXR. Peroxisome proliferator-activated
receptor a (PPARa) is a transcription factor in lipid metabolism
that is induced by FXR (60). CYP7A1 is an FXR target that
catalyzes the ﬁrst and rate-limiting step in bile acid synthesis,
which is a major consumer of cholesterol. SCD1 and FADS2 are
lipogenic enzymes that are targets of PPARa. Adipose tri-
glyceride lipase (ATGL; Pnpla2) catalyzes the ﬁrst, rate-limiting
step in hydrolysis of triglycerides to free fatty acids, which is
required to metabolize triglycerides in lipid droplets and prevent
excess lipid accumulation (57).
In FASD-fed mice, the amount of the mature SREBP-1 protein
wassigniﬁcantlyhigherinthenucleusandlowerinthecytoplasm
(Figure 6A), indicating the activation of the SREBP-1 signaling
pathway (61). The expression of Srebp1 messenger RNA
(mRNA) was not affected by diet or genotype (data not shown).
Expression of Srebp2 (Figure 6B) was higher in FASD, partic-
ularly in Mthfr
+/2 mice, suggesting that this pathway is also
activated.
Expression of Nr1h4 (FXR, Figure 6C) was reduced in FASD-
fed mice. An important target of FXR, Cyp7a1, was also re-
duced in expression in a signiﬁcant manner for both diet and
MTHFR deﬁciency (Figure 6D). Diminished expression of
Nr1h4 in FASD is consistent with the reduced expression of its
target Ppara (Figure 6E) and the Ppara targets Scd1 (Figure 6F)
and Fads2 (Figure 6G) in FASD-fed mice. Expression of Pnpla2
(ATGL, Figure 6H) was also lower due to FASD. For 2 of the
genes in lipid and cholesterol metabolism that were altered in
expression due to diet, there was also an effect of genotype
(Cyp7a1 and Srebp2). These ﬁndings suggest that genotype and
diet may have a cumulative effect on lipid gene expression that
contributes to liver injury in FASD
+/2 mice.
Methylation of 2 CpG sites in the Cyp7a1 gene was higher
in Mthfr-deﬁcient mice
Because CYP7A1 is a critical protein in cholesterol export and
its expression was dramatically reduced by diet and genotype, we
assessed a potential mechanism for the altered expression. The
methylation of 2 CpGs in the Cyp7a1 gene was examined by
bisulﬁte pyrosequencing (n = 6/group). Methylation was higher
FIGURE 3 High folic acid consumption reduces methylTHF and methylation capacity. (A) Total liver folate content did not differ between groups. (B) The
proportion of unmetabolized folic acid (percentage of total folates) in liver was w60% higher in FASD-fed mice (borderline signiﬁcant, P = 0.074). (C) The
proportion of methylTHF was signiﬁcantly lower in FASD-fed mice. (D) SAM concentrations were signiﬁcantly lower in FASD-fed mice. (E) There was
a signiﬁcant interaction between the effects of diet and Mthfr genotype on SAH concentrations, but there was no signiﬁcant difference between groups by
Tukey post hoc comparisons. (F) Methylation capacity as measured by SAM/SAH ratio. There was a signiﬁcant interaction between diet and genotype; CD
+/2
and FASD
+/+ groups were borderline signiﬁcantly different from CD
+/+ by Tukey post hoc analysis (
DP = 0.062–0.074). White bars: Mthfr
+/+; gray bars:
Mthfr
+/2. n = 4–5 per group, mean 6 SEM, analyzed by 2-factor ANOVA. CD, control diet; D, diet; FASD, folic acid–supplemented diet; G, genotype; SAH,
S-adenosylhomocysteine; SAM, S-adenosylmethionine.
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 in Mthfr
+/2 compared with Mthfr
+/+ mice by a small but signiﬁ-
cant amount; there were no differences due to diet. CpG1 meth-
ylation rose from w70% to w73% (ANOVA, genotype, P =
0.017); CpG2 rose from w50% to w53% (ANOVA, genotype,
P = 0.009). Although the observed changes were small, they may
have contributed to the observed reduction in Cyp7a1 expression.
High folic acid consumption results in a proapoptotic
environment in liver
The cytoplasmic clearing observed in FASD Mthfr
+/2 livers
may be the result of cells beginning the process of apoptosis.
Therefore, measurements of Bcl-XL (antiapoptotic) and Bak
(proapoptotic) mRNA and caspase 3/7 activity were performed
(Table 3). Expression of Bcl-XL was signiﬁcantly lower in
FASD-fed mice (ANOVA, diet, P , 0.05), whereas Bak ex-
pression was higher but not signiﬁcantly. The Bcl-XL/Bak ratio,
a marker of apoptotic potential (47, 62), declined signiﬁcantly
(Table 3), indicating a relatively proapoptotic environment
compared with CD-fed mice. Caspase 3/7 activity also tended to
be higher in FASD-fed mice (ANOVA, P = 0.064, Table 3).
Since caspase-3 can cleave SREBPs to the mature active protein
(63), our ﬁnding of higher nuclear SREBP-1 is consistent with
higher caspase activity.
DISCUSSION
Concerns have been raised that excess folic acid intake may
have unknown consequences (4, 5). We examined the effects of
a high folic acid diet on livers of Mthfr-deﬁcient mice as a model
for the high folate intake in many populations due to the com-
bination of fortiﬁcation and vitamin supplementation. We have
previously reported that plasma folate of mice fed this 103
RDA diet is w2.5-fold higher than that of mice fed the RDA
(14). Plasma folate was also w2.5-fold higher in women given
4 mg folic acid/d (103 RDA) compared with 400 mg/d (RDA)
(64). A similar increase in plasma folate was observed in the US
population post-1998 due to fortiﬁed foods and vitamin sup-
plements (65). Although plasma folate increased in FASD-fed
mice, plasma homocysteine did not decrease (14), as observed in
human studies (64), suggesting that not all of the ingested folic
acid is metabolized.
In this study, diet and Mthfr genotype had signiﬁcant effects
on hematologic parameters. The lower RBC count, hematocrit,
and hemoglobin and the higher mean corpuscular volume, par-
ticularly in FASD Mthfr
+/2 mice, are consistent with reduced
hematopoiesis, suggesting that FASD may impair nucleotide
biosynthesis in addition to methylation reactions.
We observed cumulative effects of Mthfr genotype and FASD
resulting in pseudo-MTHFR deﬁciency and reduced methylation
capacity. MTHFR protein levels were lowered by the Mthfr
+/2
genotype, as expected, and by FASD. The proportion of phos-
phorylated MTHFR, which is less active (36), was higher in
FASD-fed mice. Although we conﬁrmed that MTHFR activity is
inhibited by folic acid in vitro, suggesting that UFA might in-
hibit MTHFR in tissues, UFA in the liver was low and unlikely
to have as great an effect as the expression and phosphorylation
changes. Reduced methylTHF, SAM, and SAM/SAH ratio are
FIGURE 4 High folic acid consumption reduces messenger RNA levels of genes involved in the methylation cycle. (A) Expression of Mtr is reduced in the
livers of FASD-fed mice compared with CD-fed mice. (B) Expression of Bhmt is unaffected by diet or genotype. (C) Chdh expression is reduced because of
diet. (D) Expression of Mat1a was unchanged by genotype but tended to be lower in mice fed the FASD (P = 0.076). (E) Expression of Pemt, a major
consumer of S-adenosylmethionine, was lower because of the FASD. White bars: Mthfr
+/+; gray bars: Mthfr
+/2. n = 4–5 per group, mean 6 SEM, analyzed by
2-factor ANOVA. CD, control diet; D, diet; FASD, folic acid–supplemented diet; G, genotype.
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 consequences of lower MTHFR expression and follow the same
diet/genotype pattern (Figure 3). Altered methylation cycle gene
expression (Figure 4) adds to the lower methylation capacity of
FASD mice.
Mthfr
+/2 mice are particularly dependent on betaine-dependent
homocysteine remethylation (28), consistent with the reduced
betaine concentration in this study. However, the increased
ﬂux through betaine was insufﬁcient to maintain SAM con-
centrations. Reduced Chdh expression suggests that capacity
for betaine synthesis may not have met betaine demand. Al-
tered Chdh expression may be a mechanism to spare choline
for PtdCho synthesis via the CDP-choline pathway because
PEMT expression is reduced. This is consistent with obser-
vations in humans as the rate of homocysteine remethylation
may be reduced in patients with nonalcoholic steatohepatitis
(NASH) (66).
A major consumer of liver SAM is methylation of PE to
PtdCho by PEMT (51). PtdCho synthesis via the CDP-choline
pathway may be upregulated to compensate for reduced SAM
concentration and Pemt expression, consistent with the reduction
in PCho. Lower concentrations of PCho, PtdCho, SM, and Ly-
soPtdCho in Mthfr
+/2 mice suggest that reduced methylation
capacity due to MTHFR deﬁciency leads to greater use of be-
taine as a one-carbon donor and affects the choline-dependent
synthesis of membrane phospholipids.
PtdCho is an important component of the plasma membrane
and VLDL. Reduced PtdCho synthesis can result in liver
injury through at least 2 mechanisms. Altered PtdCho syn-
thesis is associated with lipid accumulation caused by im-
paired secretion of lipid via VLDL particles (51, 67). VLDL
particles and lipid secretion are abnormal in Mat1a
2/2 mice,
which have reduced SAM and develop NAFLD/NASH (68).
FIGURE 5 MTHFR deﬁciency alters choline and phospholipid metabolite concentrations, particularly in FASD-fed mice. The concentration of choline (A)
did not change signiﬁcantly. Betaine concentration (B) was signiﬁcantly reduced in mice fed the FASD, and there was a signiﬁcant interaction between the
effects of diet and Mthfr genotype. (C) PCho was signiﬁcantly lower in Mthfr
+/2 mice than in Mthfr
+/+ mice. (D) PtdCho concentrations were signiﬁcantly
altered by Mthfr genotype, with a signiﬁcant interaction between diet and genotype. The concentrations of SM (E) and LysoPtdCho (F), products of PtdCho
catabolism, were affected by Mthfr genotype. (E) SM concentrations were signiﬁcantly lower in Mthfr
+/2 mice, and there was a borderline signiﬁcant
interaction between diet and genotype (P = 0.053). (F) LysoPtdCho tended to be lower in Mthfr
+/2 mice (P = 0.057). White bars: Mthfr
+/+; gray bars: Mthfr
+/2.
n = 4–5 per group, mean 6 SEM, analyzed by 2-factor ANOVA. Bars without a common lowercase letter are signiﬁcantly different by Tukey post hoc, P ,
0.05. CD, control diet; D, diet; FASD, folic acid–supplemented diet; G, genotype; LysoPtdCho, lysophosphatidylcholine; MTHFR, methylenetetrahydrofolate
reductase; PCho, phosphocholine; PtdCho, phosphatidylcholine; SM, sphingomyelin.
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 Disrupted PtdCho synthesis may also alter membrane ﬂuidity
and integrity, which can damage hepatocytes. Reduced
PtdCho/PE ratios cause membrane leakage, leading to steato-
hepatitis in Pemt
2/2 mice, and are associated with NASH in
humans (69). Altered membrane integrity leads to hydropic
degeneration and hepatocyte ballooning (50, 69), forms of
degeneration observed in FASD Mthfr
+/2 livers. Reduced
PtdCho and Pemt expression in FASD
+/2 mice may have
resulted in altered membrane integrity, contributing to liver
injury.
FIGURE 6 High folic acid consumption alters expression of genes in lipid and cholesterol metabolism, particularly in Mthfr
+/2 mice. (A) Expression of
mature SREBP-1 p68 was higher in the nucleus (left) and lower in the cytoplasm (right) of the livers of mice fed the FASD, n = 6 per group, with a signiﬁcant
interaction between diet and genotype for nuclear SREBP-1 (left). Representative Western blots are shown below the graphs. (B) Srebp2 expression was higher
because of diet and Mthfr genotype, with a signiﬁcant interaction between diet and genotype. Bars without a common lowercase letter are signiﬁcantly
different by Tukey post hoc, P , 0.05. (C) Expression of the transcriptional regulator Nr1h4 (farnesoid X receptor) was lower in FASD mice. (D) Cyp7a1
expression was lower because of both diet and Mthfr genotype. (E) Expression of the transcriptional regulator Ppara was lower in FASD mice. (F) Scd1
expression was lower in FASD-fed mice. (G) Fads2 expression was lower in FASD-fed mice and tended to be lower because of Mthfr genotype (P = 0.071).
(H) Pnpla2 (adipose triglyceride lipase) expression was lower in FASD-fed mice. White bars: Mthfr
+/+; gray bars: Mthfr
+/2. n = 4–6 per group, mean 6 SEM,
analyzed by 2-factor ANOVA. CD, control diet; D, diet; FASD, folic acid–supplemented diet; G, genotype; SREBP-1, sterol regulatory element-binding
protein 1.
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 Other major mechanisms by which liver damage arises in
NAFLD/NASH are accumulation of lipids due to increased
synthesis, reduced mobilization offatty acids from lipid droplets,
and cholesterol accumulation (56, 57). We evaluated a panel of
genes in these pathways, including the major regulators SREBP-
1, SREBP-2, and FXR (Nr1h4). Dysregulation of SREBP-1 and
SREBP-2 is commonly observed in NAFLD/NASH. PtdCho is
a regulator of SREBP-1 (61); the reduction in PtdCho in FASD
Mthfr
+/2 mice would be expected to activate SREBP-1, which
would upregulate lipogenic pathways. We observed greater
SREBP-1 in the nucleus and greater SREBP-2 mRNA associ-
ated with FASD. FXR is a bile acid receptor that regulates genes
involved in the production of bile acid from cholesterol. FXR
activity, which is inversely related to severity of steatosis in
patients with NAFLD (60), downregulates Srebp1 and, in-
directly, Cyp7a1 (56, 60). Reduced Nr1h4 in FASD-fed mice
may have led to greater nuclear SREBP-1. FXR has also been
shown to upregulate Ppara (60, 70). Reduced expression of
Ppara and its targets Scd1 and Fads2 is consistent with lower
Nr1h4 expression. Expression of Pnpla2 (ATGL) was also lower
in FASD-fed mice. ATGL catalyzes the ﬁrst step of triglyceride
hydrolysis to generate free fatty acids; triglyceride hydrolysis
products upregulate PPARa signaling (71). Disruption of
Pnpla2 prevents extraction of free fatty acids from lipid drop-
lets, leading to severe steatosis and hepatic inﬂammation in mice
(57, 72).
CYP7A1 catalyzes the rate-limiting step in bile synthesis,
a major consumer of cholesterol; downregulation of CYP7A1
lowers cholesterol catabolism, raising cholesterol levels (60).
Both FASD and the Mthfr
+/2 genotype signiﬁcantly lowered
Cyp7a1 expression. Greater methylation of Cyp7a1 CpGs in
Mthfr
+/2 mice may have contributed to this effect. Reduced
CYP7A1 may result in a buildup of intracellular cholesterol,
leading to toxic effects such as altered membrane integrity;
reduced CYP7A1 is associated with greater severity of NASH
(56).
Altered lipid gene expression, activation of SREBP-1, and
disturbed PtdCho metabolism suggest that lipid accumulation
may be involvedin the hepatocyte degeneration in FASD Mthfr
+/2
mice. The heavier livers are consistent with lipid accumulation [as
in other models (for review, see da Silva et al. (51)] and en-
largement of degenerating cells. Greater liver weights correlated
with the presence of widespread degenerating hepatocytes
(Pearson correlation r = 0.502, 2-tailed P =0 . 0 0 6 ) .F A S Da l s o
induced a proapoptotic environment, which may predispose
FASD Mthfr
+/2 hepatocytes to enter apoptosis in response to
injury.
FASD may cause epigenetic changes due to reduced SAM and
aberrant DNA methylation that could affect health [reviewed in
Smith (4)]. MTHFR deﬁciency in humans and mice is associated
with altered DNA methylation (32, 73). Methylation changes
could inﬂuence expression of a variety of genes. We observed
greater methylation of 2 CpGs in Cyp7a1 that could contribute to
its reduced expression in Mthfr
+/2 mice. Similarly, Devlin et al.
(58) reported greater methylation in Fads2 associated with re-
duced Fads2 mRNA in mice fed a low-folate, high-methionine
diet.
In conclusion, high folic acid consumption in mice results in
a state of MTHFR deﬁciency, with reduced methylTHF and
methylation capacity. Findings in murine studies may not be
directly extrapolated to the human situation, but they suggest that
additional studies arewarranted, given the increased folate intake
in many populations. Many of the dramatic effects on choline
metabolites and gene expression were due to the combination of
MTHFR deﬁciency and FASD. These ﬁndings suggest a 2-hit
mechanism whereby MTHFR-deﬁcient hepatocytes are less able
to mitigate the effect of phospholipid and lipid disturbances,
leading to hepatocyte injury. MTHFR deﬁciency in hepatocytes
may set the stage for other insults (e.g., high-fat diets) that could
also leadto NAFLD. Further study is necessary because the small
sample size may be insufﬁcient to detect important genotype-diet
interactions, and the lack of correction for multiple testing in this
preliminary report raises the possibility of type I error. None-
theless, these results may have implications for the human
population, as genotype-diet interactions are known to modulate
disease risk in MTHFR 677 C.T individuals (31). It may be
important to consider variation in folate-related genes when
making recommendations for folic acid intake at both the high
and low ends of the dietary folate spectrum.
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